Back to top
more

Amplify Weight Loss Drug & Treatment ETF: (THNR)

(Delayed Data from NYSE) As of Jun 28, 2024 03:33 PM ET

$26.08 USD

26.08
2,691

-0.07 (-0.28%)

Volume: 2,691

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

After-Market: $25.01 -1.07 (-4.10 %) 7:58 PM ET

ETF Quote Details

Previous Close 26.15
Open 26.12
Bid 25.00
Ask 39.13
Day Low-High 26.06-26.12
52wk Low-High 24.92-26.43
Volume 2,691
NAV (month end) 25.27
Premium (+)/Discount (-) (month end)+0.88

Zacks Premium Research for THNR

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

 NA
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

NA

ETF Expense Ratio

Expense Ratio 0.59%
Dividend (Yield) $0.00 (0.00%)
Issuer AMPLIFY ETFS

Benchmark for THNR

VETTAFI WEIGHT LOSS DRUG & TREATMENT IND

The VettaFi Weight Loss Drug & Treatment Index comprises of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business.

Fund Summary for THNR

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

The Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance, before fees and expenses, of the VettaFi Weight Loss Drug & Treatment Index.